» Articles » PMID: 8120057

The Human CYP1A2 Gene and Induction by 3-methylcholanthrene. A Region of DNA That Supports AH-receptor Binding and Promoter-specific Induction

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1994 Mar 4
PMID 8120057
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The gene for cytochrome P4501A2 is constitutively expressed in the liver of vertebrates and shows induced expression when an organism is exposed to polycyclic aromatic hydrocarbons and halogenated hydrocarbons. To identify DNA elements regulating transcription of the human CYP1A2 gene, transient transfection experiments were conducted in the human hepatoma cell line HepG2. Dissection of the 5'-flanking portion of the CYP1A2 gene identified two regions that contributed to the overall induction by 3-methylcholanthrene. One region located at -2532/-2423 contains an xenobiotic-responsive element-like sequence, termed X1, that binds a nuclear 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible protein in HepG2 and wild type mouse Hepa-1 cells, but not in the Ah receptor nuclear translocation defective mouse C- mutant c4 cells. In addition, deletion of this region of the CYP1A2 gene reduces the 3-methylcholanthrene (3-MC)-initiated induction of chloramphenicol acetyltransferase activity in both promoter- and enhancer-specific constructs. The second responsive region is located at -2259/-1987. This region of the gene contains a second xenobiotic-responsive element-like element, but this element does not associate with the nuclear Ah receptor. However, there does exist several potential AP1 binding sites and a conserved TATA box. A DNA fragment from -2259/-1970 that contains these elements was shown to function as an efficient eukaryotic promoter, in addition to supporting 3-MC-induced promoter activity. These results suggest that Ah receptor-specific and promoter-specific elements regulate the expression of the human CYP1A2 gene.

Citing Articles

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.

Kolesar J, Peh S, Thomas L, Baburaj G, Mukherjee N, Kantamneni R Mol Cancer. 2022; 21(1):61.

PMID: 35209919 PMC: 8867675. DOI: 10.1186/s12943-022-01534-8.


Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Pascale R, Simile M, Peitta G, Seddaiu M, Feo F, Calvisi D Cancers (Basel). 2019; 11(10).

PMID: 31569678 PMC: 6826893. DOI: 10.3390/cancers11101450.


Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.

Santana Machado T, Cerini C, Burtey S Toxins (Basel). 2019; 11(4).

PMID: 30959953 PMC: 6521271. DOI: 10.3390/toxins11040209.


Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.

Dash R, Jayachandra Babu R, Srinivas N Clin Pharmacokinet. 2018; 57(11):1385-1398.

PMID: 29682695 DOI: 10.1007/s40262-018-0655-4.


A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G Clin Pharmacokinet. 2017; 57(6):749-768.

PMID: 28924743 DOI: 10.1007/s40262-017-0594-5.